181 related articles for article (PubMed ID: 35122575)
21. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
22. A multi-country cross-sectional study to assess predictors of daily versus on-demand oral pre-exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe.
Dietrich JJ; Ahmed N; Webb EL; Tshabalala G; Hornschuh S; Mulaudzi M; Atujuna M; Stranix-Chibanda L; Nematadzira T; Ssemata AS; Muhumuza R; Seeley J; Bekker LG; Weiss HA; Martinson N; Fox J;
J Int AIDS Soc; 2022 Aug; 25(8):e25975. PubMed ID: 36002910
[TBL] [Abstract][Full Text] [Related]
23. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076).
Tolley EE; Li S; Zangeneh SZ; Atujuna M; Musara P; Justman J; Pathak S; Bekker LG; Swaminathan S; Stanton J; Farrior J; Sista N
J Int AIDS Soc; 2019 Oct; 22(10):e25408. PubMed ID: 31651098
[TBL] [Abstract][Full Text] [Related]
24. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
[TBL] [Abstract][Full Text] [Related]
25. Effect of implementation strategies on pre-exposure prophylaxis persistence among female sex workers in South Africa: an interrupted time series study.
Rao A; Mhlophe H; Pretorius A; Mcingana M; Mcloughlin J; Shipp L; Baral S; Hausler H; Schwartz S; Lesko C
Lancet HIV; 2023 Dec; 10(12):e807-e815. PubMed ID: 38040479
[TBL] [Abstract][Full Text] [Related]
26. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
[TBL] [Abstract][Full Text] [Related]
27. The Use of HIV Pre-exposure Prophylaxis Among Men Accessing Routine Sexual and Reproductive Health Services in South Africa.
Cox LA; Martin CE; Nongena P; Mvelase S; Kutywayo A; Mullick S
J Adolesc Health; 2023 Dec; 73(6S):S92-S100. PubMed ID: 37953015
[TBL] [Abstract][Full Text] [Related]
28. Women's Perceptions of HIV- and Sexuality-Related Stigma in Relation to PrEP: Qualitative Findings from the Masibambane Study, Durban, South Africa.
Bergam S; Harrison AD; Benghu N; Khumalo S; Tesfay N; Exner T; Miller L; Dolezal C; Hanass-Hancock J; Hoffman S
AIDS Behav; 2022 Sep; 26(9):2881-2890. PubMed ID: 35218452
[TBL] [Abstract][Full Text] [Related]
29. Understanding Retention in the HIV Pre-Exposure Prophylaxis Cascade Among Cisgender Women.
Burns JA; Hull SJ; Inuwa A; Moriarty P; Scott RK
AIDS Patient Care STDS; 2023 Apr; 37(4):205-211. PubMed ID: 36961388
[TBL] [Abstract][Full Text] [Related]
30. Rethinking HIV prevention to prepare for oral PrEP implementation for young African women.
Celum CL; Delany-Moretlwe S; McConnell M; van Rooyen H; Bekker LG; Kurth A; Bukusi E; Desmond C; Morton J; Baeten JM
J Int AIDS Soc; 2015; 18(4 Suppl 3):20227. PubMed ID: 26198350
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial.
Munthali RJ; Stangl AL; Baron D; Barré I; Harvey S; Ramskin L; Colombini M; Naicker N; Kapiga S; Delany-Moretlwe S;
AIDS Behav; 2022 Dec; 26(12):3950-3962. PubMed ID: 35776254
[TBL] [Abstract][Full Text] [Related]
32. Discontinuation of HIV oral pre-exposure prophylaxis: findings from programmatic surveillance within two general population HIV programs in Nigeria.
Anyasi H; Idemudia A; Badru T; Onyegbule S; Isang E; Sanwo O; Pandey SR; Chiegil R; Bateganya M; Schwartz K; Njuguna N; Persaud N; Plotkin M; Iyortim I; Khamofu H
BMC Public Health; 2024 May; 24(1):1325. PubMed ID: 38755630
[TBL] [Abstract][Full Text] [Related]
33. Delivering PrEP to Young Women in a Low-Income Setting in South Africa: Lessons for Providing Both Convenience and Support.
Cassidy T; Ntuli N; Kilani C; Malabi N; Rorwana B; Mutseyekwa T; O'Connell R; Steele SJ; Ndlovu Z; Ellman T; de Azevedo V; Pfaff C; Nelson A; Duran LT
AIDS Behav; 2022 Jan; 26(1):147-159. PubMed ID: 34259963
[TBL] [Abstract][Full Text] [Related]
34. Combined HIV Adolescent Prevention Study (CHAPS): comparison of HIV pre-exposure prophylaxis regimens for adolescents in sub-Saharan Africa-study protocol for a mixed-methods study including a randomised controlled trial.
Nash S; Dietrich J; Ssemata AS; Herrera C; O'Hagan K; Else L; Chiodi F; Kelly C; Shattock R; Chirenje M; Lebina L; Khoo S; Bekker LG; Weiss HA; Gray C; Stranix-Chibanda L; Kaleebu P; Seeley J; Martinson N; Fox J;
Trials; 2020 Oct; 21(1):900. PubMed ID: 33121503
[TBL] [Abstract][Full Text] [Related]
35. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
[TBL] [Abstract][Full Text] [Related]
36. Two-Way Short Message Service (SMS) Communication May Increase Pre-Exposure Prophylaxis Continuation and Adherence Among Pregnant and Postpartum Women in Kenya.
Pintye J; Rogers Z; Kinuthia J; Mugwanya KK; Abuna F; Lagat H; Sila J; Kemunto V; Baeten JM; John-Stewart G; Unger JA
Glob Health Sci Pract; 2020 Mar; 8(1):55-67. PubMed ID: 32139420
[TBL] [Abstract][Full Text] [Related]
37. Measuring Oral Pre-exposure Prophylaxis (PrEP) Continuation Through Electronic Health Records During Program Scale-Up Among the General Population in Zambia.
Heilmann E; Okuku J; Itoh M; Hines JZ; Prieto JT; Phiri M; Watala K; Nsofu C; Luhana-Phiri M; Vlahakis N; Kabongo M; Kaliki B; Minchella PA; Musonda B
AIDS Behav; 2023 Jul; 27(7):2390-2396. PubMed ID: 36586011
[TBL] [Abstract][Full Text] [Related]
38. Feasibility of a community-based delivery model for HIV pre-exposure prophylaxis among bar patrons in rural South Africa.
Grammatico MA; Moll AP; Choi K; Springer SA; Shenoi SV
J Int AIDS Soc; 2021 Nov; 24(11):e25848. PubMed ID: 34826363
[TBL] [Abstract][Full Text] [Related]
39. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
[TBL] [Abstract][Full Text] [Related]
40. Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa.
Hosek S; Celum C; Wilson CM; Kapogiannis B; Delany-Moretlwe S; Bekker LG
J Int AIDS Soc; 2016; 19(7(Suppl 6)):21107. PubMed ID: 27760684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
